Don Hardison has served as a member of our board of directors since June 2022. From 2017 to February 2021, Mr. Hardison served as the President, Chief Executive Officer and board member of Biotheranostics, Inc., a privately-held molecular oncology diagnostics company acquired by Hologic, Inc. in February 2021. From 2010 to 2016, Mr. Hardison served as President, Chief Executive Officer and board member of Good Start Genetics, Inc., a privately-held molecular diagnostics/information company. From 2007 to 2009, he served as Executive Vice President and Chief Operating Officer of Laboratory Corporation of America (LabCorp), a publicly-traded healthcare diagnostics company, and served as President, Chief Executive Officer and board member of Exact Sciences Corporation, a publicly-traded biotechnology company, from 2000 to 2007.
Mr. Hardison currently also serves on the board of directors of BioPorto Diagnostics A/S, a publicly-traded medical technology company, and MDX Health SA, a publicly-traded molecular oncology company, since 2021. He served on the board of directors of HTG Molecular Diagnostics, a publicly-traded biotechnology company, from May 2016 to July 2023. Mr. Hardison also serves on the board of directors of and as an advisor to privately-held healthcare companies from time to time.
Mr. Hardison holds an A.B. degree in Political Science from the University of North Carolina at Chapel Hill